NFTの空売り状況は、投資家がNFTの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

NFT (AMEX:MI) 株価情報, 空売り情報

NFT Ltd operates an online electronic platform for offering and trading artwork. Through its platform, the company allows artists/art dealers/owners to access a much bigger art trading market where artists can engage with a wide range of investors. Its platform also invests in high-end artwork accessible to ordinary people without financial resources. The company's trading platforms comprise the sale of calligraphies and paintings, jewelry, and precious stones. It generates revenue in the form of services in connection with the offering and trading of artwork on its system, consisting of listing fees, trading commissions, and management fees.

NFT Ltd

Minto Apartment REIT

MIAMI BREEZE CAR CARE INC by Miami Breeze Car Care, Inc.

Millicom International Cellular SA SDR

MINT Income Fund

MICHI - United States Dollar

Mycronic AB

MICRON SOLUTIONS INC by Micron Solutions, Inc.

Micron Solutions Inc

American Century Mid Cap Growth Impact ETF

The Middleby Corp

Xtrackers S&P MidCap 400 Scored & Screened ETF

Midland Exploration Inc

Direxion Mid Cap Bull 3X Shares

MITSUBISHI ELEC CORP by Mitsubishi Electric Corp.

Mitsubishi Electric Corp

MITSUBISHI ELEC UNSP/ADR by Mitsubishi Electric Corp.

MITSUI E&S HLDGS CO LTD by Mitsui E&S Co Ltd.

Mitsui E&S Co Ltd

MITSUI E&S CO LTD U/ADR by Mitsui E&S Co Ltd.

MIFFLINBURG BANCORP INC by Mifflinburg Bancorp, Inc.

Mifflinburg Bancorp Inc

MILLENNIUM FD TECH UT NEW by MILLENNIUM FOOD TECH LTD.

Millenium Food-Tech-Ltd Partnership

VanEck Moody's Analytics IG Corporate Bond ETF

Mawson Infrastructure Group Inc. - Common Stock

Mawson Infrastructure Group Inc

MISC Bhd

MONTAGUE INTL HLDGS LTD by MONTAGUE INTERNATIONAL HOLDING LTD.

Montague International Holding Ltd

MITRA KELUARGA KARYASEHAT by Mitra Keluarga Karyasehat TBK PT

PT Mitra Keluarga Karyasehat Tbk

MIKE THE PIKE PRODS INC by Mike The Pike Productions, Inc.

Mike The Pike Productions Inc

MILLENNIUM SUSTAINALE VTR by Millennium Sustainable Ventures Corp.

Millennium Sustainable Ventures Corp

1CM Inc

MITSUBISHI LOGISTICS CORP by Mitsubishi Logistics Corp.

Mitsubishi Logistics Corp

MILITARY METALS CORP by MILITARY METALS CORP.

Military Metals Corp

Pacer Funds Trust Pacer US Cash Cows Bond ETF

Global X Millennial Consumer ETF

Mobilicom Ltd

MIM - United States Dollar

MAI - United States Dollar

MIMEDIA HLDGS INC SUB VTG by MiMedia Holdings Inc.

Mint Incorporation Limited - Class A Ordinary Shares

Mint Inc Ltd

Airspan Networks Holdings Inc

Airspan Networks Holdings Inc Warrants - Class C (01/11/2026)

MITSUBISHI MATERIALS ORD by Mitsubishi Materials Corp.

Mitsubishi Materials Corp

MITSUBISHI MTRLS UNSP/ADR by Mitsubishi Materials Corp.

Airspan Networks Holdings Inc Warrants (01/11/2026)

Nighthawk Gold Corp

MFS Intermediate Income Trust Common Stock

MFS Intermediate Income Trust

Mina Protocol - United States Dollar

MINEBEA MITSUMI INC U/ADR by Minebea Mitsumi Inc.

Minebea Mitsumi Inc

MIND Technology Inc

MIND Technology Inc 9 % Conv Pfd Registered Shs Series -A-

Minerco Inc

FiEE Inc

Trust for Professional Managers Mairs & Power Minnesota Municipal Bond ETF

PIMCO Municipal Income Opportunities Active Exchange-Traded Fund

MINOR INTL PCL ORD by Minor International Public Co., Ltd.

Minor International PCL

Minerva Gold Inc

Minor International PCL Warrants Series - 7 (31/07/2023)

PIMCO Enhanced Short Maturity Active Exchange-Traded Fund

Mint Club

MintMe.com Coin

Matthews International Funds Matthews Asia Innovators Active ETF

MERCANTILE INVST TR NEW by Mercantile Investment Trust PLC

Pioneer Municipal High Income Opportunities Fund, Inc. Common Stock

Pioneer Municipal High Income Opportunities Fund Inc.

Milbon Co Ltd

IOTA

MINOR INTL PUB CO LTD by Minor International Public Co., Ltd.

Mirion Technologies, Inc. Class A Common Stock

Mirion Technologies Inc

Mirror Protocol - United States Dollar

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals Inc

MIRAI Corp

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals Inc

Miromatrix Medical Inc

SERRANO RES LTD by Serrano Resources Ltd.

Serrano Resources Ltd

First Trust Exchange-Traded Fund First Trust Indxx Aerospace & Defense ETF

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals Inc

Mist

Minco Silver Corp

Mitani Corp

MITSUBISHI ESTATE CO by Mitsubishi Estate Co. Ltd.

Mitsubishi Estate Co Ltd

MITSUBISHI EST UNSP/ADR by Mitsubishi Estate Co. Ltd.

MITIE Group PLC

MITIE GROUP PLC UNSP/ADR by Mitie Group Plc.

Mithril

Mitesco Inc

MINT CORPORATION (THE) by Mint Corporation (The)

The Mint Corp

Mitek Systems Inc

AG Mortgage Investment Trust, Inc. 9.500% Senior Notes due 2029

MI TECHNOVATION BERHAD by MI TECHNOVATION BERHAD

MI Technovation Bhd

MITHRA PHARMACEUTICALS SA by MITHRA PHARMACEUTICALS SA

Mithra Pharmaceuticals SA

Moving iMage Technologies, Inc. Common Stock

Moving iMage Technologies Inc

MITSUI & CO LTD ORD by Mitsui & Co., Ltd.

Mitsui & Co Ltd

MITSUI & CO LTD ADR by Mitsui & Co., Ltd.

AG Mortgage Investment Trust, Inc. Common Stock

AG Mortgage Investment Trust Inc

AG Mortgage Investment Trust, Inc. 8.25% Preferred Series A

In the current market session, Lennar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) share price is at $108.37, after a 3.56% decrease. Over the past month, the stock went up by 5.46%, but over the past year, it actually fell by 29.13%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1747256430_0.png" alt="Past Year Chart" />

<h3>Evaluating Lennar P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 10.81 in the Household Durables industry, Lennar Inc. has a lower P/E ratio of 8.2. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747256430_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

A Look Into Lennar Inc's Price Over Earnings

Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Adaptimmune Therapeutics, presenting an average target of $1.52, a high estimate of $3.00, and a low estimate of $0.46. A negative shift in sentiment is evident as analysts have decreased the average price target by 35.59%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747256431_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Adaptimmune Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$0.46</td>
<td>$1.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$1.00</td>
<td>$1.50</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1.75</td>
<td>$3.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$1.50</td>
<td>$2.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$1.40</td>
<td>$3.15</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Adaptimmune Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Adaptimmune Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Adaptimmune Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Adaptimmune Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADAP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Adaptimmune Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Adaptimmune Therapeutics's Background</h2>
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
<h3>Breaking Down Adaptimmune Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Adaptimmune Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1294.81% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Adaptimmune Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2303.38% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -161.62%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -26.35%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Adaptimmune Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 6.26. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ADAP

Forecasting The Future: 6 Analyst Projections For Adaptimmune Therapeutics

In the latest quarter, 6 analysts provided ratings for PaySign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYS#NASDAQ">PAYS</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $6.54, a high estimate of $8.25, and a low estimate of $5.00. This upward trend is apparent, with the current average reflecting a 2.51% increase from the previous average price target of $6.38.
<img src="https://www.benzinga.com/files/images/story/2025/1747256423_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of PaySign by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Jon Hickman</td>
<td>Ladenburg Thalmann</td>
<td>Raises</td>
<td>Buy</td>
<td>$8.25</td>
<td>$7.25</td>
</tr>
<tr>
<td>Jacob Stephan</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to PaySign. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of PaySign compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for PaySign's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into PaySign's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PAYS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on PaySign analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About PaySign</h2>
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
<h3>Breaking Down PaySign's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, PaySign showcased positive performance, achieving a revenue growth rate of 41.0% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.91%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): PaySign's ROE stands out, surpassing industry averages. With an impressive ROE of 7.42%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.35%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.07, PaySign adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PAYS

Forecasting The Future: 6 Analyst Projections For PaySign

Morningstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) has outperformed the market over the past 15 years by 26.53% on an annualized basis producing an average annual return of 38.51%. Currently, Morningstar has a market capitalization of $13.11 billion. 
Buying $1000 In MORN: If an investor had bought $1000 of MORN stock 15 years ago, it would be worth $130,387.23 today based on a price of $306.41 for MORN at the time of writing.
<h3>Morningstar's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747256418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

MORN

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

USA Rare Earth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.04) by 375 percent.

Earnings

Earnings Misses

USAR

USA Rare Earth Q1 Adj. EPS $(0.19) Misses $(0.04) Estimate

VTAK

Catheter Precision, Inc. Common Stock Q1 EPS $(0.36) Misses $(0.20) Estimate, Sales $143.00K Miss $300.00K Estimate

Announces Preliminary Results of Consent Solicitation

Management

Barnwell Industries Shareholders Reject Attempt By Ned Sherwood To Remove And Replace Board

Iris Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.14 by 21.43 percent. This is a 42.86 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $148.10 million which missed the analyst consensus estimate of $159.37 million by 7.07 percent. This is a 172.50 percent increase over sales of $54.35 million the same period last year.

IREN

IREN Q3 EPS $0.11 Misses $0.14 Estimate, Sales $148.10M Miss $159.37M Estimate

WIIM

GCTS

GCT Semiconductor shares are trading lower after the company reported worse-than-expected Q1 financial results.

ZSPACE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZSPC#NASDAQ">ZSPC</a>) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.16) by 62.5 percent. This is a 99.63 percent increase over losses of $(70.83) per share from the same period last year. The company reported quarterly sales of $6.76 million which beat the analyst consensus estimate of $5.03 million by 34.46 percent. This is a 13.80 percent decrease over sales of $7.84 million the same period last year.

Earnings Beats

ZSPC

ZSPACE Q1 EPS $(0.26) Misses $(0.16) Estimate, Sales $6.76M Beat $5.03M Estimate

FBLG

FibroBiologics, Inc. - Common Stock Q1 EPS $(0.14) Misses $(0.11) Estimate

H&amp;R REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HR#TSX">HR</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.29 by 2.41 percent. This is a 1 percent decrease over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $205.64 million which missed the analyst consensus estimate of $236.60 million by 13.09 percent. This is a 1.85 percent decrease over sales of $209.52 million the same period last year.

TSX:HR

H&R REIT Q1 FFO $0.30 Beats $0.29 Estimate, Sales $205.64M Miss $236.60M Estimate

ICCC

ImmuCell shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

SQFT

Presidio Property Trust Q1 FFO $(0.076) Down From $(0.035) YoY, Sales $4.13M Down From $4.79M YoY

ISSC

Innovative Solutions shares are trading higher after the company reported better-than-expected Q2 financial results.

Lithium Argentina Q1 EPS $(0.04) Misses $(0.01) Estimate

Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) released its third-quarter results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/05/n45419675/cisco-reports-third-quarter-earnings">details from the report.</a> 
The Details: Cisco reported quarterly earnings of 96 cents per share, which beat the analyst consensus estimate of 92 cents. Quarterly revenue came in at $14.15 billion, which beat the Street estimate of $14.08 billion and is up from revenue of $12.70 billion from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45414265/nvidia-climbs-on-saudi-ai-investments-analyst-estimates-15-billion-to-20-billion-in-revenue?utm_source=articleShare">Nvidia Climbs On Saudi AI Investments: Analyst Estimates $15 Billion To $20 Billion In Revenue&nbsp;</a>
Cisco also reported product orders were up 20% year-over-year, up 9% excluding Splunk, with growth across all geographies and customer markets. AI Infrastructure orders taken from webscale customers exceeded $600 million, surpassing the company&#8217;s $1 billion target one quarter early. 
&#8220;Cisco once again had strong quarterly results with clear demand for our technologies,&#8221; said Chuck Robbins, chair and CEO of Cisco. &#8220;The momentum we are seeing with AI is fueled by the power of our secure networking portfolio, our trusted global partnerships, and the value we bring to our customers.&#8221;
Outlook:&nbsp;Cisco sees fourth-quarter adjusted earnings of between 96 cents and 98 cents per share, versus the 95 cent estimate, and revenue in a range of $14.5 billion and $14.7 billion, versus the $14.58 billion estimate. 
Cisco raised its fiscal 2025 EPS guidance from between $3.68 and $3.74 per share to between $3.77 and $3.79 per share, versus the $3.73 estimate. The company raised its fiscal 2025 revenue forecast from a range of $56 billion to $56.50 billion to a new range of $56.5 billion to $56.7 billion, versus the $56.47 billion estimate.
CSCO Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Cisco stock was up 3.90% at $63.68 after-hours Wednesday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45353123/quantum-stocks-are-hot-in-2025-biggest-movers-to-watch?utm_source=articleShare">Quantum Stocks Are Hot In 2025: Biggest Movers To Watch&nbsp;</a></li>
</ul>
Photo: Shutterstock

Movers

Tech

CSCO

Cisco Shares Climb After Q3 EPS, Revenue Beat Estimates: Details

FrontView REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVR#NYSE">FVR</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.28 by 7.14 percent. The company reported quarterly sales of $16.24 million which missed the analyst consensus estimate of $16.33 million by 0.53 percent.

FrontView REIT Q1 FFO $0.30 Beats $0.28 Estimate, Sales $16.24M Miss $16.33M Estimate

CTXR

Citius Pharma Q2 EPS $(1.27) Misses $0.33 Estimate

Retailer Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) may provide a better picture of the impact of tariffs on consumers when the company reports first-quarter financial results before <a href="https://www.benzinga.com/earnings">market open Thursday.</a>
Here are the analyst estimates, a look at what experts are saying ahead of the report and key items to watch.
Earnings Estimates: Analysts expect Walmart to report first-quarter revenue of $165.88 billion. That&#8217;s up from $161.51 billion in last year's first quarter, according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">from Benzinga Pro.</a>
The company has beaten analyst estimates for revenue in more than 10 straight quarters.
Analysts expect Walmart to report earnings per share of 58 cents, down from 60 cents per share in Q1 2024.
The company has beaten analyst estimates for earnings per share in five straight quarters and nine of the last ten quarters overall. The lone non-beat was earnings in line with estimates.
The company&#8217;s guidance calls for first-quarter sales to be up 3% to 4% year over year. Earnings per share range between 57 cents and 58 cents.
Read Also: <a href="https://www.benzinga.com/politics/25/05/45272436/marjorie-taylor-greene-goes-stock-shopping-again-here-are-50-stocks-the-congresswoman-bought">Marjorie Taylor Greene Goes Stock Shopping Again: 50+ Stocks The Congresswoman Bought</a>
What Experts Are Saying: In a recent note, Telsey Advisory analyst Joseph Feldman said Walmart could benefit from grocery market share gains and improving e-commerce progress in the <a href="https://www.benzinga.com/news/large-cap/25/05/45357178/walmart-analysts-strategy-curbs-price-hikes-despite-tariffs">first quarter.</a>
The analyst maintained an Outperform rating and price target for $115.
Feldman said Walmart could gain wallet share from several groups, including higher-income consumers. The analyst said Amazon and Costco showed trends of first-quarter sales being stronger for categories like electronics.
Feldman said Walmart should navigate the uncertain macroeconomic environment effectively.
Bank of America analyst Robert Ohmes said Walmart is well-equipped to handle tariffs with its pricing and automation strategies, inventory management and strong supplier relationships.
The analyst maintained a Buy rating with a $120 price target ahead of the quarterly earnings.
Ohmes said Walmart's groceries are less likely to be impacted by tariffs.
Freedom Capital Markets Chief Global Strategist Jay Woods highlighted the importance of Walmart's financial results for the market in his weekly <a href="https://jaywoods.substack.com/">newsletter</a>.
"Walmart could be one of the most telling stocks when it comes to tariff impacts when they report on Thursday," Woods said.
Woods said Walmart was cautious with guidance after the last quarter.
"Investors will be closely watching this report for strategies on managing tariff-related challenges, maintaining competitive pricing, and supply chain issues that may make stocking shelves more of a challenge."
Key Items to Watch: Tariffs commentary will undoubtedly be the biggest item in Walmart's earnings and conference call.
Outside of tariffs, investors and analysts could also look at commentary on the company's Walmart+ membership program. The subscription-based service was responsible for around 50% of online spending in the U.S. last fiscal year. This could make it a strong source of ecommerce and recurring revenue.
A report said the program is seeing increased spending per subscriber and also higher shopping frequency rates from subscribers.
Walmart+ has also helped the retailer post 11 consecutive quarters of double-digit online sales growth in the United States.
Global e-commerce sales were up 16% year-over-year in Q4; this will be a key area to watch in Q1.
WMT Price Action: Walmart stock was up 1.3% to $97.11 on Wednesday versus a 52-week trading range of $59.47 to $105.30. Walmart stock is up 7.9% year-to-date in 2025 and up over 60% in the last year. 
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/25/03/44226602/walmart-ceo-says-consumers-changing-spending-due-to-inflation-egg-prices-the-money-runs-out-before-the-month-is-gone-people-are-buying-smaller-pack-sizes">Walmart CEO Says Consumers Changing Spending Due To Inflation, Egg Prices: &#8216;The Money Runs Out Before The Month Is Gone … People Are Buying Smaller Pack Sizes&#8217;</a><a href="https://www.benzinga.com/go/plus500-futures" target="_blank" rel="noreferrer noopener"></a></li>
</ul>
Image: Shutterstock<a href="https://www.benzinga.com/go/plus500-futures" target="_blank" rel="noreferrer noopener"> </a>

Analyst Color

Price Target

Previews

Reiteration

Walmart Q1 Earnings Preview: Why Retailer Will Have 'One Of The Most Telling' Reports On Tariff Impact

Antelope Enterprise Holdings Limited - Class A Ordinary Shares

Antelope Ent Hldgs

BuzzFeed

Cheer Holding, Inc. - Class A Ordinary Share

Cheer Holding

DHI Group

Fangdd Network Group Ltd. - Class A Ordinary Shares

Fangdd Network Group

Phoenix New Media Limited American Depositary Shares, each representing 48 Class A ordinary shares.

Phoenix New Media

Giftify

Global Interactive Technologies, Inc. Common Stock - Common Stock

Comments

NFT

空売り

NFT (AMEX:MI) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル